Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / Switzerland

Actelion Agrees US$3.3bn Licensing Deal With GSK For Insomnia Drug

July 2008 | Company News Alert
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *


If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.

Swiss biopharmaceuticals firm Actelion has secured a lucrative licensing deal with GlaxoSmithKline (GSK) for its insomnia candidate almorexant. In return for worldwide marketing rights (excluding Japan) to the drug, GSK could fork out as much as US$3.3bn.